×
About 4,353 results

ALLMedicine™ Plaque Psoriasis Center

Research & Reviews  1,212 results

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale a...
https://doi.org/10.1136/bmjopen-2021-049822
BMJ Open; Eyerich K, Weisenseel P et. al.

Sep 15th, 2021 - Guselkumab is an interleukin (IL)-23 pathway blocker with proven efficacy in patients with moderate-to-severe plaque psoriasis. Early intervention with guselkumab may result in changes to the clinical disease course versus later intervention. Here...

Implications of narrowband ultraviolet B treatment on psoriasis severity and serum leve...
https://doi.org/10.1111/jocd.14446
Journal of Cosmetic Dermatology; Nada HA, Elshabrawy MM et. al.

Sep 9th, 2021 - Psoriasis is a chronic inflammatory hyper proliferative skin disease. Angiogenesis play an important role in Psoriasis pathogenesis, occurring even before plaque formation. Angiopoietins play an important role in angiogenesis and hence are describ...

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422702
BMC Health Services Research; Zagni E, Bianchi L et. al.

Sep 8th, 2021 - Psoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be...

Nomogram for accurate and quantitative prediction of the risk of psoriatic arthritis in...
https://doi.org/10.1684/ejd.2021.4095
European Journal of Dermatology : EJD; Chen Z, Wang Y et. al.

Sep 1st, 2021 - Psoriatic arthritis (PsA) is an inflammatory form of arthritis that appears approximately 7-10 years after psoriasis and remains undiagnosed in most of patients. Currently, only a few quantitative and succinct PsA-risk prediction models are availa...

see more →

Guidelines  1 results

Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway.
https://doi.org/10.1159/000512930
Dermatology (Basel, Switzerland); Maul JT, Anzengruber F et. al.

Jan 7th, 2021 - Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choic...

see more →

Drugs  123 results see all →

Clinicaltrials.gov  11 results

An Explorative Psoriasis Biomarker Study
https://clinicaltrials.gov/ct2/show/NCT04394936

Jun 14th, 2021 - Psoriasis is a common skin disorder affecting up to an estimated 3% of the world's population. The most prevalent form of psoriasis, called psoriasis vulgaris or plaque psoriasis, is characterized by the presence of sharply demarcated erythematous...

Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients
https://clinicaltrials.gov/ct2/show/NCT04398732

Oct 30th, 2020 - This study is to evaluate available local data in Iraqi patients with moderate to severe psoriasis on Enbrel treatment with regards to efficacy, treatment regimen adherence and patient characterization (i.e. age, gender, smoking status) using data...

Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT01313221

Mar 15th, 2017 - The recommended starting dose of etanercept for adult plaque psoriasis patients is a 50 mg dose given twice a week (BIW) for 3 months followed by a reduction to a maintenance dose of 50 mg once weekly (QW). While most patients with moderate to sev...

Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With Adalimumab
https://clinicaltrials.gov/ct2/show/NCT01328366

Jul 9th, 2015 - This was a multi-center, prospective, post-marketing observational study of participants with severe chronic plaque psoriasis who began adalimumab therapy in the United Kingdom. Although 153 participants enrolled in the study, data was only analyz...

see more →

News  394 results

Fast Five Quiz: Plaque Psoriasis Presentation and Diagnosis
https://www.medscape.com/viewarticle/929579

Jul 9th, 2021 - Psoriasis is a chronic, immune-mediated inflammatory skin disease. Globally, approximately 125 million people have psoriasis, which manifests in several ways (ie, plaque, flexural, guttate, pustular, or erythrodermic psoriasis). Plaque psoriasis i...

Fast Five Quiz: Plaque Psoriasis Management
https://www.medscape.com/viewarticle/923304

Jul 9th, 2021 - Plaque psoriasis is the most common form of psoriasis, a chronic inflammatory skin disorder that affects approximately 125 million individuals worldwide. It exerts a considerable burden on affected patients, including decreased quality of life and...

Biologic Treatment Mitigates PsA Risk in Patients With Psoriasis, Study Finds
https://www.medscape.com/viewarticle/953693

Jun 24th, 2021 - Patients with psoriasis treated with biological disease-modifying antirheumatic drugs had a significantly lower incidence of psoriatic arthritis (PsA) compared with those treated with phototherapy, in a study of 464 adults. Epidemiologic data show...

Fast Five Quiz: Systemic Treatments for Plaque Psoriasis
https://www.medscape.com/viewarticle/929577

Jun 14th, 2021 - Approximately 125 million people around the world have psoriasis, a chronic, relapsing inflammatory skin disorder. Several clinical variants of psoriasis are recognized, but plaque psoriasis is the most common. Psoriasis is associated with a signi...

Psoriasis Treatment With Biologics: 5 Things to Know
https://www.medscape.com/viewarticle/951993

Jun 14th, 2021 - Psoriasis affects at least 100 million people worldwide, with plaque psoriasis (also referred to as psoriasis vulgaris) being the most common form. Although many different medication options are available for psoriasis, the type of treatment presc...

see more →